Although there is inadequate evidence to link TP53 gene mutations to the immunobiological behavior and clinical features of lung cancer, there is evidence that TP53 gene mutations to alter the sensitivity of immune checkpoint inhibitors (ICIs) treatment and resistance evolution of EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLS) [6–8]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.